Pralatrexate (Pralatrexate) Patent Expiration, LOE Window & CMS Spending

Pralatrexate (Pralatrexate) by Fresenius Kabi: Multi-Source Generic Molecule, 0 AB generics, $1.4M 2024 CMS Part D & Medicaid spend, and $14,111 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($14,111 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.